A+ Science AB   Report issue

For profit Phase 2
Founded: Stockholm Germany (1997)

Organization Overview

First Clinical Trial
2014
NCT02497547
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

A+ Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

oxytocin (syntocinon) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1